Evidence map›Paper›PMID 31084622›Full record

ArticleJournal of nanobiotechnology2019

Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery.

Haijun Wang, Junzi Wu, Gareth R Williams, Qing Fan, Shiwei Niu, Jianrong Wu, Xiaotian Xie, Li-Min Zhu

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 94 papers.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 215 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Beyond autologousMolecular therapy. Oncology · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Haijun WangCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, China.
Junzi WuCollege of Basic Medicine, Yunnan University of Traditional Chinese Medicine, Kunming, 650500, China. beached@126.com.
Gareth R WilliamsUCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK.
Qing FanDepartment of Pharmacy, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, Jinan, 250117, China.
Shiwei NiuCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, China.
Jianrong WuCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, China.
Xiaotian XieCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, China.
Li-Min ZhuCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, China. lzhu@dhu.edu.cn.ORCID http://orcid.org/0000-0003-1580-6851
Donghua University · CNShandong University · CNUniversity College London · GB

Funding

Biomedical Textile Materials "111 Project" of the Ministry of Education of China B07024Science and Technology Commission of Shanghai Municipality 16410723700
6 · The paper itself

Abstract

backgroundNanoscale drug-delivery systems (DDSs) have great promise in tumor diagnosis and treatment. Platelet membrane (PLTM) biomimetic DDSs are expected to enhance retention in vivo and escape uptake by macrophages, as well as minimizing immunogenicity, attributing to the CD47 protein in PLTM sends "don't eat me" signals to macrophages. In addition, P-selectin is overexpressed on the PLTM, which would allow a PLTM-biomimetic DDS to specifically bind to the CD44 receptors upregulated on the surface of cancer cells.

resultsIn this study, porous nanoparticles loaded with the anti-cancer drug bufalin (Bu) were prepared from a chitosan oligosaccharide (CS)-poly(lactic-co-glycolic acid) (PLGA) copolymer. These were subsequently coated with platelet membrane (PLTM) to form PLTM-CS-pPLGA/Bu NPs. The PLTM-CS-pPLGA/Bu NPs bear a particle size of ~ 192 nm, and present the same surface proteins as the PLTM. Confocal microscopy and flow cytometry results revealed a greater uptake of PLTM-CS-pPLGA/Bu NPs than uncoated CS-pPLGA/Bu NPs, as a result of the targeted binding of P-selectin on the surface of the PLTM to the CD44 receptors of H22 hepatoma cells. In vivo biodistribution studies in H22-tumor carrying mice revealed that the PLTM-CS-pPLGA NPs accumulated in the tumor, because of a combination of active targeting effect and the EPR effect. The PLTM-CS-pPLGA/Bu NPs led to more effective tumor growth inhibition over other bufalin formulations.

conclusionsPlatelet membrane biomimetic nanoparticles played a promising targeted treatment of cancer with low side effect.

Indexed as

AnimalsAntineoplastic AgentsBiological TransportBiomimetic MaterialsBlood PlateletsBufanolidesCell Line, TumorCell SurvivalChitosanDelayed-Action PreparationsDrug CarriersDrug CompoundingDrug LiberationFemaleHumansHyaluronan ReceptorsAntineoplastic AgentsbufalinBufanolidesChitosanDelayed-Action PreparationsDrug CarriersHyaluronan ReceptorsMembrane ProteinsOligosaccharidesPolylactic Acid-Polyglycolic Acid CopolymerBiomimeticBufalinNanoparticlesPlatelet membraneTargeted anti-tumor drug delivery

Identifiers

PMID31084622
PMCPMC6513513
OpenAlexW2947885335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.